Affordable Access

Access to the full text

NOV/CCN3: A new adipocytokine involved in obesity-associated insulin resistance

Authors
  • Martinerie, Cécile
  • Garcia, Marie
  • Huong Do, Thi Thu
  • Antoine, Bénédicte
  • Moldes, Marthe
  • Dorothee, Guillaume
  • Kazazian, Chantal
  • Auclair, Martine
  • Buyse, Marion
  • Ledent, Tatiana
  • Marchal, Pierre-Olivier
  • Fesatidou, Maria
  • Beisseiche, Adrien
  • Koseki, Haruhiko
  • Hiraoka, Shuichi
  • Chadjichristos, Christos Evangelos
  • Blondeau, Bertrand
  • Denis, Raphael Georges
  • Serge Luquet
  • Fève, Bruno
Type
Published Article
Journal
Diabetes
Publisher
American Diabetes Association
Publication Date
Jun 10, 2016
Volume
65
Issue
9
Pages
2502–2515
Identifiers
DOI: 10.2337/db15-0617
PMID: 27284105
OAI: oai:HAL:hal-01339017v1
Source
USPC - SET - SVS
Keywords
License
Green
External links

Abstract

Identification of new adipokines that potentially link obesity to insulin resistance represents a major challenge. We have recently shown that NOV/CCN3, a multifunctional matricellular protein, is synthesized and secreted by adipose tissue, with plasma levels highly correlated with body mass index. NOV has been previously involved in tissue repair, fibrotic and inflammatory diseases, and cancer. However, its role in energy homeostasis remains unknown. We investigated the metabolic phenotype of NOV-/- mice fed a standard or high fat diet (HFD). Strikingly, the weight of NOV-/- mice was markedly lower than that of WT mice but only on a HFD. This was related to a significant decrease in fat mass associated with an increased proportion of smaller adipocytes and to a higher expression of genes involved in energy expenditure. NOV-/- mice fed a HFD displayed improved glucose tolerance and insulin sensitivity. Interestingly, the absence of NOV was associated with a change in macrophages profile (M1-like to M2-like) and in marked decrease in adipose tissue expression of several proinflammatory cytokines and chemokines and to an enhanced insulin signaling. Conversely, treatment of adipocytes by NOV increased chemokine expression. Altogether, these results show that NOV is a new adipocytokine that could be involved in obesity-associated insulin-resistance.

Report this publication

Statistics

Seen <100 times